Resorbable Vascular Scaffolds Market Report 2026

The resorbable vascular scaffolds market size has grown rapidly in recent years. It will grow from $0.51 billion in 2025 to $0.58 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to advancements in polymer-based medical materials, increasing prevalence of cardiovascular diseases, expansion of interventional cardiology procedures, growing adoption of minimally invasive treatments, availability of clinical evidence supporting scaffold use.

The resorbable vascular scaffolds market size is expected to see rapid growth in the next few years. It will grow to $0.92 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing demand for safer alternatives to permanent stents, rising investments in cardiovascular device innovation, expansion of bioresorbable material research, growing focus on patient-specific treatment solutions, increasing regulatory support for advanced vascular devices. Major trends in the forecast period include increasing development of bioabsorbable scaffold materials, rising adoption of next-generation vascular implants, growing focus on temporary vessel support technologies, expansion of clinical trials for resorbable devices, enhanced emphasis on long-term patient outcomes.

The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the resorbable vascular scaffolds market in the coming years. Cardiovascular diseases are influenced by factors such as unhealthy lifestyle habits, aging populations, hypertension, high cholesterol levels, diabetes, smoking, and genetic susceptibility. Resorbable vascular scaffolds are transforming cardiovascular disease treatment by providing temporary structural support to reopen blocked arteries while gradually dissolving over time, thereby minimizing long-term complications associated with permanent implants and supporting natural vessel healing and restored functionality. For example, in June 2024, according to data released by the American Heart Association, Inc., a US-based nonprofit organization, more than 150 million people in the United States are projected to have poor dietary habits by 2050. This trend is expected to contribute to an almost 40% rise in adult obesity, increasing from 43.6% to 60.6%, and over a 60% rise in childhood obesity, from 20.6% to 33%. Additionally, 61% of adults are projected to develop cardiovascular disease, with the most significant obesity growth observed among adults aged 20 to 64. Therefore, the growing prevalence of cardiovascular diseases is fueling the expansion of the resorbable vascular scaffolds market.

Major companies operating in the resorbable vascular scaffolds market are focusing on the development of magnesium-based scaffolds to enhance biocompatibility and provide improved mechanical support. Magnesium scaffolds support natural vessel healing while lowering inflammation and reducing complications commonly associated with conventional polymer-based scaffolds. For instance, in March 2024, Biotronik, a Germany-based medical device company, received Breakthrough Device designation from the US Food and Drug Administration (FDA) for its Freesolve below-the-knee resorbable magnesium scaffold (BTK RMS). The Freesolve RMS is designed for patients with chronic limb-threatening ischemia (CLTI) and offers an advanced treatment option for below-the-knee vascular interventions. It incorporates BIOmag magnesium alloy and Orsiro drug-eluting stent (DES) coating technology, which improves safety, deliverability, and vessel support while providing short-term scaffolding to resist vessel recoil during the healing process.

In April 2023, Abbott Laboratories, a US-based medical device company, acquired Cardiovascular Systems Inc. for an undisclosed amount. Through this acquisition, Abbott aims to broaden its vascular product portfolio, enhance treatment options, and strengthen its ability to care for patients with peripheral and coronary artery disease. Cardiovascular Systems Inc. is a US-based medical device company specializing in the development of innovative atherectomy systems for the treatment of peripheral and coronary artery diseases.

Major companies operating in the resorbable vascular scaffolds market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, Biotronik, Lepu Medical Technology, Biosensors International, Blue Medical, Reva Medical, Elixir Medical, S3V Vascular Technologies, Amaranth Medical Inc., Meril Life Sciences Pvt. Ltd., Arterius Limited, Zorion Medical, Kyoto Medical Planning Co. Ltd., ICON Interventional Systems, MicroPort Scientific Corporation, Cook Medical, Cardinal Health Interventional Division, Medinol Ltd., Alvimedica, OrbusNeich Medical.

North America was the largest region in the resorbable vascular scaffolds market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the resorbable vascular scaffolds market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the resorbable vascular scaffolds market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the resorbable vascular scaffolds market by increasing costs of imported biomedical polymers, precision manufacturing equipment, coating materials, and testing instruments. Medical device manufacturers in North America and Europe are most affected due to dependence on specialized imported materials, while Asia-Pacific faces cost pressure on scaffold production and exports. These tariffs are raising device development and production costs. However, they are also encouraging domestic material innovation, regional manufacturing expansion, and localized supply chains for advanced cardiovascular implants.

The resorbable vascular scaffolds market research report is one of a series of new reports that provides resorbable vascular scaffolds market statistics, including resorbable vascular scaffolds industry global market size, regional shares, competitors with a resorbable vascular scaffolds market share, detailed resorbable vascular scaffolds market segments, market trends and opportunities, and any further data you may need to thrive in the resorbable vascular scaffolds industry. This resorbable vascular scaffolds market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Resorbable vascular scaffolds are medical devices used in the treatment of vascular diseases by providing temporary structural support to blood vessels. These scaffolds gradually dissolve after serving their intended purpose, helping to reduce the risks linked to permanent implants. By supporting natural vessel healing and restoring normal blood flow, they present a safer and more effective alternative to conventional stents.

The main product designs of resorbable vascular scaffolds include multilumen and single-lumen configurations. Multilumen resorbable vascular scaffolds are advanced bioresorbable devices featuring multiple channels or lumens that are designed to offer improved support, maintain blood flow, and encourage natural vessel healing in complex vascular conditions. The materials used in these scaffolds include poly-glycolic acid, poly-L-lactic acid, and poly-L-lactic-co-glycolic acid, along with deployment techniques such as balloon-expandable and self-expandable methods. These devices are used in the treatment of coronary artery disease, peripheral vascular disease, and pulmonary artery disease, and are utilized by end users such as ambulatory surgical centers, hospitals, and specialty clinics.

The resorbable vascular scaffolds market consists of sales of resorbable scaffold systems, resorbable scaffold delivery devices, and bioresorbable stents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.